Osteoprotegerin and mortality in type 2 diabetic patients
about
Osteoprotegerin (OPG) as a biomarker for diabetic cardiovascular complications.The influence of vitamin D analogs on calcification modulators, N-terminal pro-B-type natriuretic peptide and inflammatory markers in hemodialysis patients: a randomized crossover study.Osteoprotegerin as a marker of atherosclerosis: a systematic update.Elevated levels of plasma osteoprotegerin are associated with all-cause mortality risk and atherosclerosis in patients with stages 3 to 5 chronic kidney diseaseThe presence of methylation quantitative trait loci indicates a direct genetic influence on the level of DNA methylation in adipose tissueOsteoprotegerin and coronary artery disease in type 2 diabetic patients with microalbuminuria.Osteoprotegerin in Cardiometabolic Disorders.Matrix γ-carboxyglutamate protein and Fetuin-A, in wet type age-related macular degenerationPlasma concentrations of extracellular matrix protein fibulin-1 are related to cardiovascular risk markers in chronic kidney disease and diabetes.Osteoprotegerin is an independent predictor of vascular events in Finnish adults with type 1 diabetesAortic flow propagation velocity, epicardial fat thickness, and osteoprotegerin level to predict subclinical atherosclerosis in patients with nonalcoholic fatty liver disease.The role of osteoprotegerin in cardiovascular disease.Neuropathy and the vascular-bone axis in diabetes: lessons from Charcot osteoarthropathy.Osteoprotegerin as a marker of cardiovascular risk in children and adolescents with type 1 diabetes.Association of plasma osteoprotegerin and adiponectin with arterial function, cardiac function and metabolism in asymptomatic type 2 diabetic men.Comparison of osteoprotegerin and vascular endothelial growth factor in normoalbuminuric Type 1 diabetic and control subjects.Osteoprotegerin/sRANKL Signaling System in Pulmonary Sarcoidosis: A Bronchoalveolar Lavage Study.High osteoprotegerin levels predict MACCE in STEMI patients, but are not associated with myocardial salvage.
P2860
Q27692635-5DF9C208-A62B-495D-A35B-ACA5E3B9555AQ34059805-2F2EEB51-BE21-4C03-A2A8-809F4852D431Q34234163-D701CF57-8A96-40D6-84E8-A44E32B82A39Q34502634-1FE8FD3A-8DB4-4CC0-81A8-3EF976FDC99CQ34595002-4F8805E3-1624-47C7-ABAA-6AA9A49656A5Q35183117-8F4356C7-AC11-422B-9266-767117698CA6Q35640787-1D3E60B8-EE20-4AC1-B64A-DBA1EF6B134FQ35691938-C464F3DE-71FA-4F67-A2FE-E1C08F3FC9A2Q36604574-FB617835-4621-4875-8D75-7A37EC5C165DQ36942172-EC2B9C97-F0BC-47D5-A59E-98853F6204BFQ37664577-308837C1-6DD7-4FA8-9682-DB8752927CF5Q38056541-D70632CC-0802-46BA-903A-A0E1052F552DQ38148953-A55753A6-E534-472F-AF5D-52A249164974Q39824391-4A99715B-1835-41C3-A242-F5FA3071F4B1Q42013167-CA2E5004-9A53-4FD9-8828-92218BC47449Q44637237-5B050B80-D736-4B7D-91DD-61E8FA9C24FAQ51337112-CB72D630-2196-4071-A3AA-6181FC2E9A69Q53068399-655A3D39-2498-4412-9A23-6AB04D783B11
P2860
Osteoprotegerin and mortality in type 2 diabetic patients
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Osteoprotegerin and mortality in type 2 diabetic patients
@ast
Osteoprotegerin and mortality in type 2 diabetic patients
@en
Osteoprotegerin and mortality in type 2 diabetic patients
@nl
type
label
Osteoprotegerin and mortality in type 2 diabetic patients
@ast
Osteoprotegerin and mortality in type 2 diabetic patients
@en
Osteoprotegerin and mortality in type 2 diabetic patients
@nl
prefLabel
Osteoprotegerin and mortality in type 2 diabetic patients
@ast
Osteoprotegerin and mortality in type 2 diabetic patients
@en
Osteoprotegerin and mortality in type 2 diabetic patients
@nl
P2093
P2860
P50
P356
P1433
P1476
Osteoprotegerin and mortality in type 2 diabetic patients
@en
P2093
Hans-Henrik Parving
Henrik Reinhard
Mari-Anne Gall
Maria Lajer
P2860
P304
P356
10.2337/DC10-0858
P407
P577
2010-10-07T00:00:00Z